Compare · DXCM vs NVAC
DXCM vs NVAC
Side-by-side comparison of DexCom Inc. (DXCM) and NorthView Acquisition Corporation (NVAC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and NVAC operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $23.76B, about 100.8x NVAC ($235.6M).
- DXCM has hit the wire 4 times in the past 4 weeks while NVAC has been quiet.
- DXCM has more recent analyst coverage (25 ratings vs 0 for NVAC).
- Company
- DexCom Inc.
- NorthView Acquisition Corporation
- Price
- -
- -
- Market cap
- $23.76B
- $235.6M
- 1M return
- -6.78%
- -
- 1Y return
- -13.41%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2022
- News (4w)
- 4
- 0
- Recent ratings
- 25
- 0
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
NorthView Acquisition Corporation
NorthView Acquisition Corporation does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It also intends to focus its search on businesses that are focused on healthcare sector. The company was incorporated in 2021 and is based in New York, New York. NorthView Acquisition Corporation is a subsidiary of NorthView Sponsor I, LLC.
Latest DXCM
- SEC Form 4 filed by Brown Michael Jon
- SEC Form DEFA14A filed by DexCom Inc.
- SEC Form DEF 14A filed by DexCom Inc.
- SEC Form 144 filed by DexCom Inc.
- Dexcom Schedules First Quarter 2026 Earnings Release and Conference Call for April 30, 2026 at 4:30 p.m. Eastern Time
- Amendment: SEC Form SCHEDULE 13G/A filed by DexCom Inc.
- Dexcom upgraded by Evercore ISI with a new price target
- SEC Form 4 filed by Brown Michael Jon
- Dexcom Showcases Breakthrough Outcomes for People With Type 2 Diabetes and Product Roadmap at ATTD 2026
- EVP, Chief Financal Officer Sylvain Jereme M was granted 48,774 shares and covered exercise/tax liability with 18,950 shares, increasing direct ownership by 24% to 153,292 units (SEC Form 4)
Latest NVAC
- SEC Form 3 filed by new insider Asarpota Rajesh
- New insider Hwang Ben Chung-Bin claimed ownership of 844,228 shares (SEC Form 3)
- NorthView Acquisition Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Change in Shell Company Status, Other Events
- SEC Form DEF 14C filed by NorthView Acquisition Corporation
- SEC Form CERT filed by NorthView Acquisition Corporation
- SEC Form 8-A12B filed by NorthView Acquisition Corporation
- SEC Form 425 filed by NorthView Acquisition Corporation
- NorthView Acquisition Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 25-NSE filed by NorthView Acquisition Corporation
- SEC Form 424B3 filed by NorthView Acquisition Corporation